1. Lopez, A.D. and C.C. Murray, The global burden of disease, 1990-2020. Nat Med, 1998. 4 (11): p. 1241-3.
2. Lerner, D.J. and W.B. Kannel, Patterns of coronary heart disease morbidity and mortality in the sexes: a 26-year follow-up of the Framingham population. Am Heart J, 1986. 111 (2): p. 383-90.
3. Lloyd-Jones, D.M., et al., Lifetime risk of developing coronary heart disease. Lancet, 1999. 353 (9147): p. 89-92.
4. Kalin, M.F. and B. Zumoff, Sex hormones and coronary disease: a review of the clinical studies. Steroids, 1990. 55 (8): p. 330-52.
5. Manson, J.E., et al., Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med, 2003. 349 (6): p. 523-34.
6. Stefanick, M.L., Estrogens and progestins: background and history, trends in use, and guidelines and regimens approved by the US Food and Drug Administration. Am J Med, 2005. 118 Suppl 12B : p. 64-73.
7. Hayward, C.S., R.P. Kelly, and P. Collins, The roles of gender, the menopause and hormone replacement on cardiovascular function. Cardiovasc Res, 2000. 46 (1): p. 28-49.
8. Bhasin, S. and W.J. Bremner, Clinical review 85: Emerging issues in androgen replacement therapy. J Clin Endocrinol Metab, 1997. 82 (1): p. 3-8.
9. Davis, S., Androgen replacement in women: a commentary. J Clin Endocrinol Metab, 1999. 84 (6): p. 1886-91.
10. Mendoza, S.G., et al., Estradiol, testosterone, apolipoproteins, lipoprotein cholesterol, and lipolytic enzymes in men with premature myocardial infarction and angiographically assessed coronary occlusion. Artery, 1983. 12 (1): p. 1-23.
11. Barth, J.D., et al., Post-heparin lipases, lipids and related hormones in men undergoing coronary arteriography to assess atherosclerosis. Atherosclerosis, 1983. 48 (3): p. 235-41.
12. Hromadova, M., T. Hacik, and I. Riecansky, Concentration of lipid, apoprotein-B and testosterone in patients with coronarographic findings. Klin Wochenschr, 1985. 63 (20): p. 1071-4.
13. Breier, C., et al., Essential role of post-heparin lipoprotein lipase activity and of plasma testosterone in coronary artery disease. Lancet, 1985. 1 (8440): p. 1242-4.
14. Aksut, S.V., et al., The determination of serum estradiol, testosterone and progesterone in acute myocardial infarction. Jpn Heart J, 1986. 27 (6): p. 825-37.
15. Sewdarsen, M., et al., Sex hormone levels in young Indian patients with myocardial infarction. Arteriosclerosis, 1986. 6 (4): p. 418-21.
16. Chute, C.G., et al., Sex hormones and coronary artery disease. Am J Med, 1987. 83 (5): p. 853-9.
17. Hamalainen, E., et al., Serum lipoproteins, sex hormones and sex hormone binding globulin in middle-aged men of different physical fitness and risk of coronary heart disease. Atherosclerosis, 1987. 67 (2-3): p. 155-62.
18. Lichtenstein, M.J., et al., Sex hormones, insulin, lipids, and prevalent ischemic heart disease. Am J Epidemiol, 1987. 126 (4): p. 647-57.
19. Swartz, C.M. and M.A. Young, Low serum testosterone and myocardial infarction in geriatric male inpatients. J Am Geriatr Soc, 1987. 35 (1): p. 39-44.
20. Sewdarsen, M., I. Jialal, and R.K. Naidu, The low plasma testosterone levels of young Indian infarct survivors are not due to a primary testicular defect. Postgrad Med J, 1988. 64 (750): p. 264-6.
21. Sewdarsen, M., et al., Abnormalities in sex hormones are a risk factor for premature manifestation of coronary artery disease in South African Indian men. Atherosclerosis, 1990. 83 (2-3): p. 111-7.
22. Rice, T., et al., Cincinnati myocardial infarction and hormone family study: family resemblance for testosterone in random and MI families. Am J Med Genet, 1993. 47 (4): p. 542-9.
23. Phillips, G.B., B.H. Pinkernell, and T.Y. Jing, The association of hypotestosteronemia with coronary artery disease in men. Arterioscler Thromb, 1994. 14 (5): p. 701-6.
24. Zhao, S.P. and X.P. Li, The association of low plasma testosterone level with coronary artery disease in Chinese men. Int J Cardiol, 1998. 63 (2): p. 161-4.
25. English, K.M., et al., Men with coronary artery disease have lower levels of androgens than men with normal coronary angiograms. Eur Heart J, 2000. 21 (11): p. 890-4.
26. Hak, A.E., et al., Low levels of endogenous androgens increase the risk of atherosclerosis in elderly men: the Rotterdam study. J Clin Endocrinol Metab, 2002. 87 (8): p. 3632-9.
27. Luria, M.H., et al., Relationship between sex hormones, myocardial infarction, and occlusive coronary disease. Arch Intern Med, 1982. 142 (1): p. 42-4.
28. Labropoulos, B., et al., Serum sex hormones in patients with coronary disease and their relationship to known factors causing atherosclerosis. Cardiology, 1982. 69 (2): p. 98-103.
29. Zumoff, B., et al., Abnormal hormone levels in men with coronary artery disease. Arteriosclerosis, 1982. 2 (1): p. 58-67.
30. Phillips, G.B., et al., Association of hyperestrogenemia and coronary heart disease in men in the Framingham cohort. Am J Med, 1983. 74 (5): p. 863-9.
31. Heller, R.F., et al., Relationship of high density lipoprotein cholesterol with total and free testosterone and sex hormone binding globulin. Acta Endocrinol (Copenh), 1983. 104 (2): p. 253-6.
32. Small, M., et al., Serum oestradiol and ischaemic heart disease--relationship with myocardial infarction but not coronary atheroma or haemostasis. Q J Med, 1985. 57 (223): p. 775-82.
33. Franzen, J. and G. Fex, Low serum apolipoprotein A-I in acute myocardial infarction survivors with normal HDL cholesterol. Atherosclerosis, 1986. 59 (1): p. 37-42.
34. Baumann, G., et al., Plasma estrogens, androgens, and von Willebrand factor in men on chronic hemodialysis. Int J Artif Organs, 1988. 11 (6): p. 449-53.
35. Slowinska-Srzednicka, J., et al., Decreased plasma dehydroepiandrosterone sulfate and dihydrotestosterone concentrations in young men after myocardial infarction. Atherosclerosis, 1989. 79 (2-3): p. 197-203.
36. Cengiz, K., M. Alvur, and U. Dindar, Serum creatine phosphokinase, lactic dehydrogenase, estradiol, progesterone and testosterone levels in male patients with acute myocardial infarction and unstable angina pectoris. Mater Med Pol, 1991. 23 (3): p. 195-8.
37. Hauner, H., et al., Sex hormone concentrations in men with angiographically assessed coronary artery disease--relationship to obesity and body fat distribution. Klin Wochenschr, 1991. 69 (14): p. 664-8.
38. Mitchell, L.E., et al., Evidence for an association between dehydroepiandrosterone sulfate and nonfatal, premature myocardial infarction in males. Circulation, 1994. 89 (1): p. 89-93.
39. Marques-Vidal, P., et al., Relationships of plasminogen activator inhibitor activity and lipoprotein(a) with insulin, testosterone, 17 beta-estradiol, and testosterone binding globulin in myocardial infarction patients and healthy controls. J Clin Endocrinol Metab, 1995. 80 (6): p. 1794-8.
40. Feldman, H.A., et al., Low dehydroepiandrosterone sulfate and heart disease in middle-aged men: cross-sectional results from the Massachusetts Male Aging Study. Ann.Epidemiol, 1998. 8 (4): p. 217-228.
41. Kabakci, G., et al., Relationship between endogenous sex hormone levels, lipoproteins and coronary atherosclerosis in men undergoing coronary angiography. Cardiology, 1999. 92 (4): p. 221-5.
42. Schuler-Luttmann, S., et al., Insulin-like growth factor-binding protein-3 is associated with the presence and extent of coronary arteriosclerosis. Arterioscler Thromb Vasc Biol, 2000. 20 (4): p. E10-E15.
43. Turhan, S., et al., The association between androgen levels and premature coronary artery disease in men. Coron Artery Dis, 2007. 18 (3): p. 159-62.
44. Fallah, N., et al., Nonlinear association between serum testosterone levels and coronary artery disease in Iranian men. Eur J Epidemiol, 2009. 24 (6): p. 297-306.
45. Gu, H.F., Y.M. Yang, and Z.R. Xu, [Relationship between androgen levels and pathological changes of coronary atherosclerosis in elderly males]. Zhejiang Da Xue Xue Bao Yi Xue Ban, 2007. 36 (4): p. 382-5.
46. He, H., et al., Sex hormone ratio changes in men and postmenopausal women with coronary artery disease. Menopause, 2007. 14 (3 Pt 1): p. 385-90.
47. Rosano, G.M., et al., Low testosterone levels are associated with coronary artery disease in male patients with angina. Int J Impot Res, 2007. 19 (2): p. 176-82.
48. Cauley, J.A., et al., Usefulness of sex steroid hormone levels in predicting coronary artery disease in men. Am J Cardiol, 1987. 60 (10): p. 771-7.
49. Barrett-Connor, E. and K.T. Khaw, Endogenous sex hormones and cardiovascular disease in men. A prospective population-based study. Circulation, 1988. 78 (3): p. 539-45.
50. Phillips, G.B., K. Yano, and G.N. Stemmermann, Serum sex hormone levels and myocardial infarction in the Honolulu Heart Program. Pitfalls in prospective studies on sex hormones. J Clin Epidemiol, 1988. 41 (12): p. 1151-6.
51. Contoreggi, C.S., et al., Plasma levels of estradiol, testosterone, and DHEAS do not predict risk of coronary artery disease in men. J Androl, 1990. 11 (5): p. 460-70.
52. Yarnell, J.W., et al., Endogenous sex hormones and ischemic heart disease in men. The Caerphilly prospective study. Arterioscler Thromb, 1993. 13 (4): p. 517-20.
53. Hautanen, A., et al., Adrenal androgens and testosterone as coronary risk factors in the Helsinki Heart Study. Atherosclerosis, 1994. 105 (2): p. 191-200.
54. Harman, S.M., et al., Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab, 2001. 86 (2): p. 724-31.
55. Arnlov, J., et al., Endogenous sex hormones and cardiovascular disease incidence in men. Ann Intern Med, 2006. 145 (3): p. 176-84.
56. Vikan, T., et al., Endogenous sex hormones and the prospective association with cardiovascular disease and mortality in men: the Tromso Study. Eur J Endocrinol, 2009. 161 (3): p. 435-42.
57. Smith, G.D., et al., Cortisol, testosterone, and coronary heart disease: prospective evidence from the Caerphilly study. Circulation, 2005. 112 (3): p. 332-40.
58. Araujo, A.B., et al., Sex steroids and all-cause and cause-specific mortality in men. Arch Intern Med, 2007. 167 (12): p. 1252-60.
59. Laughlin, G.A., E. Barrett-Connor, and J. Bergstrom, Low serum testosterone and mortality in older men. J Clin Endocrinol Metab, 2008. 93 (1): p. 68-75.
60. Khaw, K.T., et al., Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) Prospective Population Study. Circulation, 2007. 116 (23): p. 2694-701.
61. Smyth, C.M. and W.J. Bremner, Klinefelter syndrome. Arch Intern Med, 1998. 158 (12): p. 1309-14.
62. Bojesen, A., S. Juul, and C.H. Gravholt, Prenatal and postnatal prevalence of Klinefelter syndrome: a national registry study. J Clin Endocrinol Metab, 2003. 88 (2): p. 622-6.
63. Handelsman, D.J. and P.Y. Liu, Klinefelter's syndrome--a microcosm of male reproductive health. J Clin Endocrinol Metab, 2006. 91 (4): p. 1220-2.
64. Bojesen, A., et al., Increased mortality in Klinefelter syndrome. J Clin Endocrinol Metab, 2004. 89 (8): p. 3830-4.
65. Swerdlow, A.J., et al., Mortality in patients with Klinefelter syndrome in Britain: a cohort study. J Clin Endocrinol Metab, 2005. 90 (12): p. 6516-22.
66. Bojesen, A., et al., The metabolic syndrome is frequent in Klinefelter's syndrome and is associated with abdominal obesity and hypogonadism. Diabetes Care, 2006. 29 (7): p. 1591-8.
67. Hamilton, J.B. and G.E. Mestler, Mortality and survival: comparison of eunuchs with intact men and women in a mentally retarded population. J Gerontol, 1969. 24 (4): p. 395-411.
68. van Kesteren, P.J., et al., Mortality and morbidity in transsexual subjects treated with cross-sex hormones. Clin Endocrinol (Oxf), 1997. 47 (3): p. 337-42.
69. Smith, M.R., et al., Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab, 2002. 87 (2): p. 599-603.
70. Smith, M.R., H. Lee, and D.M. Nathan, Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab, 2006. 91 (4): p. 1305-8.
71. Keating, N.L., A.J. O'Malley, and M.R. Smith, Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol, 2006. 24 (27): p. 4448-56.
72. Braga-Basaria, M., et al., Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol, 2006. 24 (24): p. 3979-83.
73. D'Amico, A.V., et al., Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol, 2007. 25 (17): p. 2420-5.
74. Saigal, C.S., et al., Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer, 2007. 110 (7): p. 1493-500.
75. Tsai, H.K., et al., Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst, 2007. 99 (20): p. 1516-24.
76. Nanda, A., et al., Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction. JAMA, 2009. 302 (8): p. 866-73.
77. Wilson, J.D., Androgen abuse by athletes. Endocr Rev, 1988. 9 (2): p. 181-99.
78. Handelsman, D.J. and A. Heather, Androgen abuse in sports. Asian J Androl, 2008. 10 (3): p. 403-15.
79. Nilsson, S., et al., The prevalence of the use of androgenic anabolic steroids by adolescents in a county of Sweden. Eur J Public Health, 2001. 11 (2): p. 195-7.
80. Yesalis, C.E. and M.S. Bahrke, Doping among adolescent athletes. Baillieres Best Pract Res Clin Endocrinol Metab, 2000. 14 (1): p. 25-35.
81. Dhar, R., et al., Cardiovascular toxicities of performance-enhancing substances in sports. Mayo Clin Proc, 2005. 80 (10): p. 1307-15.
82. Fineschi, V., et al., Anabolic steroid abuse and cardiac sudden death: a pathologic study. Arch Pathol Lab Med, 2001. 125 (2): p. 253-5.
83. Sullivan, M.L., et al., The cardiac toxicity of anabolic steroids. Prog Cardiovasc Dis, 1998. 41 (1): p. 1-15.
84. Fernandez-Balsells, M.M., et al., Clinical review 1: Adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. J Clin Endocrinol Metab. 95 (6): p. 2560-75.
85. Basaria, S., et al., Adverse events associated with testosterone administration. N Engl J Med. 363 (2): p. 109-22.
86. Srinivas-Shankar, U., et al., Effects of testosterone on muscle strength, physical function, body composition, and quality of life in intermediate-frail and frail elderly men: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab. 95 (2): p. 639-50.
87. Rosano, G.M., et al., Acute anti-ischemic effect of testosterone in men with coronary artery disease. Circulation, 1999. 99 (13): p. 1666-70.
88. Webb, C.M., et al., Effect of acute testosterone on myocardial ischemia in men with coronary artery disease. Am J Cardiol, 1999. 83 (3): p. 437-9, A9.
89. Webb, C.M., et al., Effects of testosterone on coronary vasomotor regulation in men with coronary heart disease. Circulation, 1999. 100 (16): p. 1690-6.
90. Jaffe, M.D., Effect of testosterone cypionate on postexercise ST segment depression. Br Heart J, 1977. 39 (11): p. 1217-22.
91. Wu, S.Z. and X.Z. Weng, Therapeutic effects of an androgenic preparation on myocardial ischemia and cardiac function in 62 elderly male coronary heart disease patients. Chin Med J (Engl), 1993. 106 (6): p. 415-8.
92. English, K.M., et al., Low-dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina: A randomized, double-blind, placebo-controlled study. Circulation, 2000. 102 (16): p. 1906-11.
93. Webb, C.M., et al., Effects of oral testosterone treatment on myocardial perfusion and vascular function in men with low plasma testosterone and coronary heart disease. Am J Cardiol, 2008. 101 (5): p. 618-24.
94. Mathur, A., et al., Long-term benefits of testosterone replacement therapy on angina threshold and atheroma in men. Eur J Endocrinol, 2009. 161 (3): p. 443-9.
95. Pugh, P.J., T.H. Jones, and K.S. Channer, Acute haemodynamic effects of testosterone in men with chronic heart failure. Eur Heart J, 2003. 24 (10): p. 909-15.
96. Caminiti, G., et al., Effect of long-acting testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance, and baroreflex sensitivity in elderly patients with chronic heart failure a double-blind, placebo-controlled, randomized study. J Am Coll Cardiol, 2009. 54 (10): p. 919-27.
97. Malkin, C.J., et al., Testosterone therapy in men with moderate severity heart failure: a double-blind randomized placebo controlled trial. Eur Heart J, 2006. 27 (1): p. 57-64.
98. Birkenhager-Gillesse, E.G., J. Derksen, and A.M. Lagaay, Dehydroepiandrosterone sulphate (DHEAS) in the oldest old, aged 85 and over. Ann.N Y.Acad.Sci., 1994. 719 : p. 543-552.
99. Vermeulen, A., Dehydroepiandrosterone sulfate and aging. Ann.N Y.Acad.Sci., 1995. 774 : p. 121-127.
100. Khaw, K.T., Dehydroepiandrosterone, dehydroepiandrosterone sulphate and cardiovascular disease. J Endocrinol, 1996. 150 Suppl : p. S149-S153.
101. Nafziger, A.N., D.M. Herrington, and T.L. Bush, Dehydroepiandrosterone and dehydroepiandrosterone sulfate: their relation to cardiovascular disease. Epidemiol Rev, 1991. 13 : p. 267-293.
102. Ebeling, P. and V.A. Koivisto, Physiological importance of dehydroepiandrosterone. Lancet, 1994. 343 (8911): p. 1479-1481.
103. Labrie, F., et al., DHEA and the intracrine formation of androgens and estrogens in peripheral target tissues: its role during aging. Steroids, 1998. 63 (5-6): p. 322-328.
104. Barrett-Connor, E., K.T. Khaw, and S.S. Yen, A prospective study of dehydroepiandrosterone sulfate, mortality, and cardiovascular disease. N Engl J Med, 1986. 315 (24): p. 1519-1524.
105. Herrington, D.M., et al., Plasma dehydroepiandrosterone and dehydroepiandrosterone sulfate in patients undergoing diagnostic coronary angiography. J Am Coll.Cardiol., 1990. 16 (6): p. 862-870.
106. LaCroix, A.Z., K. Yano, and D.M. Reed, Dehydroepiandrosterone sulfate, incidence of myocardial infarction, and extent of atherosclerosis in men. Circulation, 1992. 86 (5): p. 1529-1535.
107. Ishihara, F., et al., Role of adrenal androgens in the development of arteriosclerosis as judged by pulse wave velocity and calcification of the aorta. Cardiology, 1992. 80 (5-6): p. 332-338.
108. Herrington, D.M., Dehydroepiandrosterone and coronary atherosclerosis. Ann.N Y.Acad.Sci., 1995. 774 : p. 271-280.
109. Barrett-Connor, E. and D. Goodman-Gruen, The epidemiology of DHEAS and cardiovascular disease. Ann.N Y.Acad.Sci., 1995. 774 : p. 259-270.
110. Newcomer, L.M., et al., Dehydroepiandrosterone sulfate and the risk of myocardial infarction in US male physicians: a prospective study. Am J Epidemiol, 1994. 140 (10): p. 870-875.
111. Berr, C., et al., Relationships of dehydroepiandrosterone sulfate in the elderly with functional, psychological, and mental status, and short-term mortality: a French community-based study. Proc.Natl.Acad.Sci.U.S.A, 1996. 93 (23): p. 13410-13415.
112. Trivedi, D.P. and K.T. Khaw, Dehydroepiandrosterone sulfate and mortality in elderly men and women. J Clin Endocrinol Metab, 2001. 86 (9): p. 4171-4177.
113. Phillips, G.B., B.H. Pinkernell, and T.Y. Jing, The association of hypotestosteronemia with coronary artery disease in men. Arterioscler Thromb, 1994. 14 (5): p. 701-706.
114. Jansson, J.H., T.K. Nilsson, and O. Johnson, von Willebrand factor, tissue plasminogen activator, and dehydroepiandrosterone sulphate predict cardiovascular death in a 10 year follow up of survivors of acute myocardial infarction. Heart, 1998. 80 (4): p. 334-337.
115. Tilvis, R.S., M. Kahonen, and M. Harkonen, Dehydroepiandrosterone sulfate, diseases and mortality in a general aged population. Aging (Milano.), 1999. 11 (1): p. 30-34.
116. Kiechl, S., et al., No association between dehydroepiandrosterone sulfate and development of atherosclerosis in a prospective population study (Bruneck Study). Arterioscler Thromb Vasc Biol, 2000. 20 (4): p. 1094-1100.
117. Moriyama, Y., et al., The plasma levels of dehydroepiandrosterone sulfate are decreased in patients with chronic heart failure in proportion to the severity. J Clin Endocrinol Metab, 2000. 85 (5): p. 1834-1840.
118. Rice, S.P., et al., Effects of dehydroepiandrosterone replacement on vascular function in primary and secondary adrenal insufficiency: a randomized crossover trial. J Clin Endocrinol Metab, 2009. 94 (6): p. 1966-1972.
119. Kawano, H., et al., Dehydroepiandrosterone supplementation improves endothelial function and insulin sensitivity in men. J Clin Endocrinol Metab, 2003. 88 (7): p. 3190-3195.
120. Baulieu, E.E., et al., Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: contribution of the DHEAge Study to a sociobiomedical issue. Proc.Natl.Acad.Sci.U.S.A, 2000. 97 (8): p. 4279-4284.
121. Larsen, B.A., et al., Effect of testosterone on atherogenesis in cholesterol-fed rabbits with similar plasma cholesterol levels. Atherosclerosis, 1993. 99 (1): p. 79-86.
122. Bruck, B., et al., Gender-specific differences in the effects of testosterone and estrogen on the development of atherosclerosis in rabbits. Arterioscler Thromb Vasc Biol, 1997. 17 (10): p. 2192-2199.
123. Alexandersen, P., et al., Natural androgens inhibit male atherosclerosis: a study in castrated, cholesterol-fed rabbits. Circ Res, 1999. 84 (7): p. 813-819.
124. Toda, T., et al., Ultrastructural changes in the comb and aorta of chicks fed excess testosterone. Atherosclerosis, 1984. 51 (1): p. 47-57.
125. Adams, M.R., J.K. Williams, and J.R. Kaplan, Effects of androgens on coronary artery atherosclerosis and atherosclerosis-related impairment of vascular responsiveness. Arterioscler Thromb Vasc Biol, 1995. 15 (5): p. 562-570.
126. Gonzales, R.J., D.N. Krause, and S.P. Duckles, Testosterone suppresses endothelium-dependent dilation of rat middle cerebral arteries. Am J Physiol Heart Circ Physiol, 2004. 286 (2): p. H552-H560.
127. Elhage, R., et al., 17 beta-estradiol prevents fatty streak formation in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol, 1997. 17 (11): p. 2679-2684.
128. von, D.G., et al., Atherosclerosis in apolipoprotein E-deficient mice is decreased by the suppression of endogenous sex hormones. Horm.Metab Res, 2001. 33 (2): p. 110-114.
129. Nathan, L., et al., Testosterone inhibits early atherogenesis by conversion to estradiol: critical role of aromatase. Proc.Natl.Acad.Sci.U.S.A, 2001. 98 (6): p. 3589-3593.
130. Arad, Y., et al., Dehydroepiandrosterone feeding prevents aortic fatty streak formation and cholesterol accumulation in cholesterol-fed rabbit. Arteriosclerosis, 1989. 9 (2): p. 159-166.
131. Eich, D.M., et al., Inhibition of accelerated coronary atherosclerosis with dehydroepiandrosterone in the heterotopic rabbit model of cardiac transplantation. Circulation, 1993. 87 (1): p. 261-269.
132. Hayashi, T., et al., Dehydroepiandrosterone retards atherosclerosis formation through its conversion to estrogen: the possible role of nitric oxide. Arterioscler Thromb Vasc Biol, 2000. 20 (3): p. 782-792.
133. Simon, D., et al., Association between plasma total testosterone and cardiovascular risk factors in healthy adult men: The Telecom Study. J Clin Endocrinol Metab, 1997. 82 (2): p. 682-5.
134. Phillips, G.B., et al., Sex hormones and hemostatic risk factors for coronary heart disease in men with hypertension. J Hypertens, 1993. 11 (7): p. 699-702.
135. Barrett-Connor, E., Lower endogenous androgen levels and dyslipidemia in men with non-insulin-dependent diabetes mellitus. Ann Intern Med, 1992. 117 (10): p. 807-11.
136. Haffner, S.M., et al., Obesity, body fat distribution and sex hormones in men. Int J Obes Relat Metab Disord, 1993. 17 (11): p. 643-9.
137. Barrett-Connor, E.L., Testosterone and risk factors for cardiovascular disease in men. Diabete Metab, 1995. 21 (3): p. 156-61.
138. Gyllenborg, J., et al., Cardiovascular risk factors in men: The role of gonadal steroids and sex hormone-binding globulin. Metabolism, 2001. 50 (8): p. 882-8.
139. Muller, M., et al., Endogenous sex hormones and cardiovascular disease in men. J Clin Endocrinol Metab, 2003. 88 (11): p. 5076-86.
140. Dhindsa, S., et al., Frequent occurrence of hypogonadotropic hypogonadism in type 2 diabetes. J Clin Endocrinol Metab, 2004. 89 (11): p. 5462-8.
141. Grossmann, M., et al., Low testosterone levels are common and associated with insulin resistance in men with diabetes. J Clin Endocrinol Metab, 2008. 93 (5): p. 1834-40.
142. Andersson, B., et al., Testosterone concentrations in women and men with NIDDM. Diabetes Care, 1994. 17 (5): p. 405-11.
143. Hautanen, A., Synthesis and regulation of sex hormone-binding globulin in obesity. Int J Obes Relat Metab Disord, 2000. 24 Suppl 2 : p. S64-70.
144. Bjorntorp, P., The regulation of adipose tissue distribution in humans. Int J Obes Relat Metab Disord, 1996. 20 (4): p. 291-302.
145. Kapoor, D., et al., Androgens, insulin resistance and vascular disease in men. Clin Endocrinol (Oxf), 2005. 63 (3): p. 239-50.
146. Leenen, R., et al., Visceral fat accumulation in relation to sex hormones in obese men and women undergoing weight loss therapy. J Clin Endocrinol Metab, 1994. 78 (6): p. 1515-20.
147. Hammoud, A., et al., Effect of Roux-en-Y gastric bypass surgery on the sex steroids and quality of life in obese men. J Clin Endocrinol Metab, 2009. 94 (4): p. 1329-32.
148. Pitteloud, N., et al., Increasing insulin resistance is associated with a decrease in Leydig cell testosterone secretion in men. J Clin Endocrinol Metab, 2005. 90 (5): p. 2636-41.
149. Katznelson, L., et al., Using quantitative CT to assess adipose distribution in adult men with acquired hypogonadism. AJR Am J Roentgenol, 1998. 170 (2): p. 423-7.
150. Chamberlain, N.L., E.D. Driver, and R.L. Miesfeld, The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. Nucleic Acids Res, 1994. 22 (15): p. 3181-6.
151. Beilin, J., et al., Effect of the androgen receptor CAG repeat polymorphism on transcriptional activity: specificity in prostate and non-prostate cell lines. J Mol Endocrinol, 2000. 25 (1): p. 85-96.
152. Zitzmann, M., et al., The CAG repeat polymorphism in the AR gene affects high density lipoprotein cholesterol and arterial vasoreactivity. J Clin Endocrinol Metab, 2001. 86 (10): p. 4867-73.
153. Hersberger, M., et al., The CAG repeat polymorphism in the androgen receptor gene is associated with HDL-cholesterol but not with coronary atherosclerosis or myocardial infarction. Clin Chem, 2005. 51 (7): p. 1110-5.
154. Zitzmann, M., et al., The CAG repeat polymorphism in the androgen receptor gene modulates body fat mass and serum concentrations of leptin and insulin in men. Diabetologia, 2003. 46 (1): p. 31-9.
155. Stanworth, R.D., et al., Androgen receptor CAG repeat polymorphism is associated with serum testosterone levels, obesity and serum leptin in men with type 2 diabetes. Eur J Endocrinol, 2008. 159 (6): p. 739-46.
156. Alevizaki, M., et al., The androgen receptor gene CAG polymorphism is associated with the severity of coronary artery disease in men. Clin Endocrinol (Oxf), 2003. 59 (6): p. 749-55.
157. Huhtaniemi, I.T., et al., Increased estrogen rather than decreased androgen action is associated with longer androgen receptor CAG repeats. J Clin Endocrinol Metab, 2009. 94 (1): p. 277-84.
158. Page, S.T., et al., The androgen receptor gene CAG repeat polymorphism does not predict increased risk of heart disease: longitudinal results from the Massachusetts Male Ageing Study. Clin Endocrinol (Oxf), 2006. 65 (3): p. 333-9.
159. Wu, F.C. and A. von Eckardstein, Androgens and coronary artery disease. Endocr Rev, 2003. 24 (2): p. 183-217.
160. Allan, C.A., B.J. Strauss, and R.I. McLachlan, Body composition, metabolic syndrome and testosterone in ageing men. Int J Impot Res, 2007. 19 (5): p. 448-57.
161. Allan, C.A., et al., Testosterone therapy prevents gain in visceral adipose tissue and loss of skeletal muscle in nonobese aging men. J Clin Endocrinol Metab, 2008. 93 (1): p. 139-46.
162. Munzer, T., et al., Effects of GH and/or sex steroid administration on abdominal subcutaneous and visceral fat in healthy aged women and men. J Clin Endocrinol Metab, 2001. 86 (8): p. 3604-10.
163. Marin, P., et al., The effects of testosterone treatment on body composition and metabolism in middle-aged obese men. Int J Obes Relat Metab Disord, 1992. 16 (12): p. 991-7.
164. Schroeder, E.T., et al., Effects of an oral androgen on muscle and metabolism in older, community-dwelling men. Am J Physiol Endocrinol Metab, 2003. 284 (1): p. E120-8.
165. Dieudonne, M.N., et al., Opposite effects of androgens and estrogens on adipogenesis in rat preadipocytes: evidence for sex and site-related specificities and possible involvement of insulin-like growth factor 1 receptor and peroxisome proliferator-activated receptor gamma2. Endocrinology, 2000. 141 (2): p. 649-56.
166. Whitsel, E.A., et al., Intramuscular testosterone esters and plasma lipids in hypogonadal men: a meta-analysis. Am J Med, 2001. 111 (4): p. 261-9.
167. Schleich, F. and J.J. Legros, Effects of androgen substitution on lipid profile in the adult and aging hypogonadal male. Eur J Endocrinol, 2004. 151 (4): p. 415-24.
168. Isidori, A.M., et al., Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta-analysis. Clin Endocrinol (Oxf), 2005. 63 (3): p. 280-93.
169. von Eckardstein, A., J.R. Nofer, and G. Assmann, High density lipoproteins and arteriosclerosis. Role of cholesterol efflux and reverse cholesterol transport. Arterioscler Thromb Vasc Biol, 2001. 21 (1): p. 13-27.
170. Langer, C., et al., Testosterone up-regulates scavenger receptor BI and stimulates cholesterol efflux from macrophages. Biochem Biophys Res Commun, 2002. 296 (5): p. 1051-7.
171. Tan, K.C., S.W. Shiu, and A.W. Kung, Alterations in hepatic lipase and lipoprotein subfractions with transdermal testosterone replacement therapy. Clin Endocrinol (Oxf), 1999. 51 (6): p. 765-9.
172. Buchter, D., et al., Effects of testosterone suppression in young men by the gonadotropin releasing hormone antagonist cetrorelix on plasma lipids, lipolytic enzymes, lipid transfer proteins, insulin, and leptin. Exp Clin Endocrinol Diabetes, 1999. 107 (8): p. 522-9.
173. Flynn, M.A., et al., Dehydroepiandrosterone replacement in aging humans. J Clin Endocrinol Metab, 1999. 84 (5): p. 1527-33.
174. Arlt, W., et al., Dehydroepiandrosterone supplementation in healthy men with an age-related decline of dehydroepiandrosterone secretion. J Clin Endocrinol Metab, 2001. 86 (10): p. 4686-92.
175. Danesh, J., R. Collins, and R. Peto, Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. Circulation, 2000. 102 (10): p. 1082-5.
176. Anderson, R.A., E.M. Wallace, and F.C. Wu, Effect of testosterone enanthate on serum lipoproteins in man. Contraception, 1995. 52 (2): p. 115-9.
177. Angelin, B., Therapy for lowering lipoprotein (a) levels. Curr Opin Lipidol, 1997. 8 (6): p. 337-41.
178. von Eckardstein, A., et al., Suppression of endogenous testosterone in young men increases serum levels of high density lipoprotein subclass lipoprotein A-I and lipoprotein(a). J Clin Endocrinol Metab, 1997. 82 (10): p. 3367-72.
179. Barud, W., et al., Inverse relationship between total testosterone and anti-oxidized low density lipoprotein antibody levels in ageing males. Atherosclerosis, 2002. 164 (2): p. 283-8.
180. Dockery, F., et al., Testosterone suppression in men with prostate cancer is associated with increased arterial stiffness. Aging Male., 2002. 5 (4): p. 216-222.
181. Dockery, F., et al., Androgen deprivation in males is associated with decreased central arterial compliance and reduced central systolic blood pressure. J Hum Hypertens, 2000. 14 (6): p. 395-7.
182. Dockery, F., et al., Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia. Clin Sci (Lond), 2003. 104 (2): p. 195-201.
183. Smith, J.C., et al., The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J Clin Endocrinol Metab, 2001. 86 (9): p. 4261-4267.
184. Hougaku, H., et al., Relationship between androgenic hormones and arterial stiffness, based on longitudinal hormone measurements. Am J Physiol Endocrinol Metab, 2006. 290 (2): p. E234-E242.
185. Zhu, X.D., B. Bonet, and R.H. Knopp, 17beta-Estradiol, progesterone, and testosterone inversely modulate low-density lipoprotein oxidation and cytotoxicity in cultured placental trophoblast and macrophages. Am J Obstet Gynecol, 1997. 177 (1): p. 196-209.
186. Vicencio, J.M., et al., Testosterone induces an intracellular calcium increase by a nongenomic mechanism in cultured rat cardiac myocytes. Endocrinology, 2006. 147 (3): p. 1386-95.
187. Singh, A.B., et al., The effects of varying doses of T on insulin sensitivity, plasma lipids, apolipoproteins, and C-reactive protein in healthy young men. J Clin Endocrinol Metab, 2002. 87 (1): p. 136-43.
188. Liu, P.Y., et al., Do reproductive hormones modify insulin sensitivity and metabolism in older men? A randomized, placebo-controlled clinical trial of recombinant human chorionic gonadotropin. Eur J Endocrinol, 2003. 148 (1): p. 55-66.
189. Ridker, P.M., Evaluating novel cardiovascular risk factors: can we better predict heart attacks? Ann Intern Med, 1999. 130 (11): p. 933-7.
190. Anderson, R.A., C.A. Ludlam, and F.C. Wu, Haemostatic effects of supraphysiological levels of testosterone in normal men. Thromb Haemost, 1995. 74 (2): p. 693-7.
191. Smith, A.M., et al., Testosterone does not adversely affect fibrinogen or tissue plasminogen activator (tPA) and plasminogen activator inhibitor-1 (PAI-1) levels in 46 men with chronic stable angina. Eur J Endocrinol, 2005. 152 (2): p. 285-91.
192. Eri, L.M., P. Urdal, and A.G. Bechensteen, Effects of the luteinizing hormone-releasing hormone agonist leuprolide on lipoproteins, fibrinogen and plasminogen activator inhibitor in patients with benign prostatic hyperplasia. J Urol, 1995. 154 (1): p. 100-4.
193. Winkler, U.H., Effects of androgens on haemostasis. Maturitas, 1996. 24 (3): p. 147-55.
194. Agledahl, I., et al., Plasma free tissue factor pathway inhibitor (TFPI) levels and TF-induced thrombin generation ex vivo in men with low testosterone levels. Thromb Haemost, 2009. 101 (3): p. 471-7.
195. McCrohon, J.A., et al., Androgen receptor expression is greater in macrophages from male than from female donors. A sex difference with implications for atherogenesis. Circulation, 2000. 101 (3): p. 224-6.
196. Lieberherr, M. and B. Grosse, Androgens increase intracellular calcium concentration and inositol 1,4,5-trisphosphate and diacylglycerol formation via a pertussis toxin-sensitive G-protein. J Biol Chem, 1994. 269 (10): p. 7217-23.
197. Corretti, M.C., et al., Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: A report of the International Brachial Artery Reactivity Task Force. Journal of the American College of Cardiology, 2002. 39 (2): p. 257-265.
198. Akishita, M., et al., Low testosterone level is an independent determinant of endothelial dysfunction in men. Hypertens.Res, 2007. 30 (11): p. 1029-1034.
199. Karakitsos, D., et al., Androgen deficiency and endothelial dysfunction in men with end-stage kidney disease receiving maintenance hemodialysis. Am J Nephrol., 2006. 26 (6): p. 536-543.
200. Leifke, E., et al., Effects of normalization of plasma testosterone levels in hypogonadal men on plasma levels and urinary excretion of asymmetric dimethylarginine (ADMA). Horm.Metab Res, 2008. 40 (1): p. 56-59.
201. Foresta, C., et al., Reduced number of circulating endothelial progenitor cells in hypogonadal men. J Clin Endocrinol Metab, 2006. 91 (11): p. 4599-4602.
202. Ong, P.J., et al., Testosterone enhances flow-mediated brachial artery reactivity in men with coronary artery disease. Am J Cardiol., 2000. 85 (2): p. 269-272.
203. Bernini, G., et al., Vascular reactivity in congenital hypogonadal men before and after testosterone replacement therapy. J Clin Endocrinol Metab, 2006. 91 (5): p. 1691-1697.
204. Zitzmann, M., M. Brune, and E. Nieschlag, Vascular reactivity in hypogonadal men is reduced by androgen substitution. J Clin Endocrinol Metab, 2002. 87 (11): p. 5030-5037.
205. Sader, M.A., et al., Physiological testosterone replacement and arterial endothelial function in men. Clin Endocrinol (Oxf), 2003. 59 (1): p. 62-67.
206. Halushka, P.V., et al., Testosterone regulation of platelet and vascular thromboxane A2 receptors. Agents Actions Suppl, 1995. 45 : p. 19-26.
207. Masuda, A., R. Mathur, and P.V. Halushka, Testosterone increases thromboxane A2 receptors in cultured rat aortic smooth muscle cells. Circ Res, 1991. 69 (3): p. 638-643.
208. Matsuda, K., et al., Sex steroid regulation of thromboxane A2 receptors in cultured rat aortic smooth muscle cells. Prostaglandins, 1995. 49 (3): p. 183-196.
209. Higashiura, K., et al., Inhibition of testosterone 5 alpha-reductase: evidence for tissue-specific regulation of thromboxane A2 receptors. J Pharmacol.Exp.Ther., 1996. 279 (3): p. 1386-1391.
210. Higashiura, K., R.S. Mathur, and P.V. Halushka, Gender-related differences in androgen regulation of thromboxane A2 receptors in rat aortic smooth-muscle cells. J Cardiovasc.Pharmacol., 1997. 29 (3): p. 311-315.
211. Honda, H., T. Unemoto, and H. Kogo, Different mechanisms for testosterone-induced relaxation of aorta between normotensive and spontaneously hypertensive rats. Hypertension, 1999. 34 (6): p. 1232-1236.
212. Zhou, P., et al., Testosterone deprivation by castration impairs expression of voltage-dependent potassium channels in rat aorta. Eur J Pharmacol., 2008. 593 (1-3): p. 87-91.
213. Han, D.H., et al., Effect of testosterone on potassium channel opening in human corporal smooth muscle cells. J Sex Med, 2008. 5 (4): p. 822-832.
214. Hall, J., et al., Selective inhibition of L-type Ca2+ channels in A7r5 cells by physiological levels of testosterone. Endocrinology, 2006. 147 (6): p. 2675-2680.
215. Perusquia, M. and C.M. Villalon, Possible role of Ca2+ channels in the vasodilating effect of 5beta-dihydrotestosterone in rat aorta. Eur J Pharmacol., 1999. 371 (2-3): p. 169-178.
216. Scragg, J.L., et al., Testosterone is a potent inhibitor of L-type Ca(2+) channels. Biochem.Biophys.Res Commun., 2004. 318 (2): p. 503-506.
217. Perusquia, M., et al., Role of endothelium in the vasodilating effect of progestins and androgens on the rat thoracic aorta. Gen.Pharmacol., 1996. 27 (1): p. 181-185.
218. Tep-areenan, P., D.A. Kendall, and M.D. Randall, Mechanisms of vasorelaxation to testosterone in the rat aorta. Eur J Pharmacol., 2003. 465 (1-2): p. 125-132.
219. Jones, R.D., et al., Testosterone inhibits the prostaglandin F2alpha-mediated increase in intracellular calcium in A7r5 aortic smooth muscle cells: evidence of an antagonistic action upon store-operated calcium channels. J Endocrinol, 2003. 178 (3): p. 381-393.
220. Crews, J.K. and R.A. Khalil, Antagonistic effects of 17 beta-estradiol, progesterone, and testosterone on Ca2+ entry mechanisms of coronary vasoconstriction. Arterioscler Thromb Vasc Biol, 1999. 19 (4): p. 1034-1040.
221. Murphy, J.G. and R.A. Khalil, Decreased [Ca(2+)](i) during inhibition of coronary smooth muscle contraction by 17beta-estradiol, progesterone, and testosterone. J Pharmacol.Exp.Ther., 1999. 291 (1): p. 44-52.
222. Jones, R.D., et al., Testosterone-induced coronary vasodilatation occurs via a non-genomic mechanism: evidence of a direct calcium antagonism action. Clin Sci.(Lond), 2004. 107 (2): p. 149-158.
223. Kopp, J., et al., Regulation of neuropeptide Y Y1 receptors by testosterone in vascular smooth muscle cells in rat testis. Neuroendocrinology, 2008. 88 (3): p. 216-226.
224. Wakasugi, M., et al., The effects of sex hormones on the synthesis of prostacyclin (PGI2) by vascular tissues. Prostaglandins, 1989. 37 (4): p. 401-410.
225. Wells, K.E., R. Miguel, and J.J. Alexander, Sex hormones affect the calcium signaling response of human arterial cells to LDL. J Surg.Res, 1996. 63 (1): p. 64-72.
226. Lane, H.A., et al., Impaired vasoreactivity in bodybuilders using androgenic anabolic steroids. Eur J Clin Invest, 2006. 36 (7): p. 483-488.
227. Fu, L., Q.P. Gao, and J.X. Shen, Relationship between testosterone and indexes indicating endothelial function in male coronary heart disease patients. Asian J Androl, 2008. 10 (2): p. 214-218.
228. De, P.G., et al., Free testosterone plasma levels are negatively associated with the intima-media thickness of the common carotid artery in overweight and obese glucose-tolerant young adult men. Int.J Obes.Relat Metab Disord., 2003. 27 (7): p. 803-807.
229. Svartberg, J., et al., Low testosterone levels are associated with carotid atherosclerosis in men. J Intern Med, 2006. 259 (6): p. 576-582.
230. Fukui, M., et al., Association between serum testosterone concentration and carotid atherosclerosis in men with type 2 diabetes. Diabetes Care, 2003. 26 (6): p. 1869-1873.
231. Muller, M., et al., Endogenous sex hormones and progression of carotid atherosclerosis in elderly men. Circulation, 2004. 109 (17): p. 2074-2079.
232. Makinen, J., et al., Increased carotid atherosclerosis in andropausal middle-aged men. J Am Coll.Cardiol., 2005. 45 (10): p. 1603-1608.
233. Eller, N.H., B. Netterstrom, and P. Allerup, Progression in intima media thickness--the significance of hormonal biomarkers of chronic stress. Psychoneuroendocrinology, 2005. 30 (8): p. 715-723.
234. Demirbag, R., et al., The inverse relationship between thoracic aortic intima media thickness and testosterone level. Endocr Res, 2005. 31 (4): p. 335-344.
235. Ronnemaa, T., et al., Serum lipoprotein composition, hormones, and the synthesis of glycosaminoglycans by human aortic smooth muscle cells. Artery, 1980. 8 (4): p. 323-328.
236. Hashimura, K., et al., Androgens stimulate human vascular smooth muscle cell proteoglycan biosynthesis and increase lipoprotein binding. Endocrinology, 2005. 146 (4): p. 2085-2090.
237. Natoli, A.K., et al., Sex steroids modulate human aortic smooth muscle cell matrix protein deposition and matrix metalloproteinase expression. Hypertension, 2005. 46 (5): p. 1129-1134.
238. Grumbach, M.M. and R.J. Auchus, Estrogen: consequences and implications of human mutations in synthesis and action. J Clin Endocrinol Metab, 1999. 84 (12): p. 4677-94.
239. Harada, N., et al., Localized expression of aromatase in human vascular tissues. Circ Res, 1999. 84 (11): p. 1285-91.
240. Diano, S., et al., Aromatase and estrogen receptor immunoreactivity in the coronary arteries of monkeys and human subjects. Menopause, 1999. 6 (1): p. 21-8.
241. Hodges, Y.K., et al., Estrogen receptors alpha and beta: prevalence of estrogen receptor beta mRNA in human vascular smooth muscle and transcriptional effects. Circulation, 2000. 101 (15): p. 1792-8.
242. Morishima, A., et al., Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. J Clin Endocrinol Metab, 1995. 80 (12): p. 3689-98.
243. Carani, C., et al., Effect of testosterone and estradiol in a man with aromatase deficiency. N Engl J Med, 1997. 337 (2): p. 91-5.
244. Smith, E.P., et al., Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N Engl J Med, 1994. 331 (16): p. 1056-61.
245. Sudhir, K., et al., Premature coronary artery disease associated with a disruptive mutation in the estrogen receptor gene in a man. Circulation, 1997. 96 (10): p. 3774-7.
246. Sudhir, K., et al., Endothelial dysfunction in a man with disruptive mutation in oestrogen-receptor gene. Lancet, 1997. 349 (9059): p. 1146-7.
247. Ohlsson, C., et al., Obesity and disturbed lipoprotein profile in estrogen receptor-alpha-deficient male mice. Biochem Biophys Res Commun, 2000. 278 (3): p. 640-5.
248. Nemoto, Y., et al., Altered expression of fatty acid-metabolizing enzymes in aromatase-deficient mice. J Clin Invest, 2000. 105 (12): p. 1819-25.
249. Heine, P.A., et al., Increased adipose tissue in male and female estrogen receptor-alpha knockout mice. Proc Natl Acad Sci U S A, 2000. 97 (23): p. 12729-34.
250. Rubanyi, G.M., et al., Vascular estrogen receptors and endothelium-derived nitric oxide production in the mouse aorta. Gender difference and effect of estrogen receptor gene disruption. J Clin Invest, 1997. 99 (10): p. 2429-37.
251. Nilsson, B.O., et al., Increased magnitude of relaxation to oestrogen in aorta from oestrogen receptor beta knock-out mice. J Endocrinol, 2000. 166 (2): p. R5-9.
252. White, M.M., et al., Estrogen, progesterone, and vascular reactivity: potential cellular mechanisms. Endocr Rev, 1995. 16 (6): p. 739-51.
253. Sudhir, K. and P.A. Komesaroff, Clinical review 110: Cardiovascular actions of estrogens in men. J Clin Endocrinol Metab, 1999. 84 (10): p. 3411-5.
254. Nathan, L. and G. Chaudhuri, Estrogens and atherosclerosis. Annu Rev Pharmacol Toxicol, 1997. 37 : p. 477-515.
255. Shaul, P.W., Novel role of estrogen receptors in vascular endothelium. Semin Perinatol, 2000. 24 (1): p. 70-4.
256. Phillips, G.B., B.H. Pinkernell, and T.Y. Jing, The association of hyperestrogenemia with coronary thrombosis in men. Arterioscler Thromb Vasc Biol, 1996. 16 (11): p. 1383-7.
257. Tivesten, A., et al., Circulating estradiol is an independent predictor of progression of carotid artery intima-media thickness in middle-aged men. J Clin Endocrinol Metab, 2006. 91 (11): p. 4433-7.
258. Tivesten, A., et al., Low serum testosterone and high serum estradiol associate with lower extremity peripheral arterial disease in elderly men. The MrOS Study in Sweden. J Am Coll Cardiol, 2007. 50 (11): p. 1070-6.
259. Tivesten, A., et al., Low serum testosterone and estradiol predict mortality in elderly men. J Clin Endocrinol Metab, 2009. 94 (7): p. 2482-8.
260. Jankowska, E.A., et al., Circulating estradiol and mortality in men with systolic chronic heart failure. JAMA, 2009. 301 (18): p. 1892-901.
261. Phillips, G.B., T. Jing, and S.B. Heymsfield, Relationships in men of sex hormones, insulin, adiposity, and risk factors for myocardial infarction. Metabolism, 2003. 52 (6): p. 784-90.
262. Sluss, P.M., et al., Mass spectrometric and physiological validation of a sensitive, automated, direct immunoassay for serum estradiol using the Architect. Clin Chim Acta, 2008. 388 (1-2): p. 99-105.
263. Huggins, C. and C.V. Hodges, Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol, 2002. 167 (2 Pt 2): p. 948-51; discussion 952.
264. Huggins, C. and P.J. Clark, Quantitative Studies of Prostatic Secretion : Ii. The Effect of Castration and of Estrogen Injection on the Normal and on the Hyperplastic Prostate Glands of Dogs. J Exp Med, 1940. 72 (6): p. 747-62.
265. Cox, R.L. and E.D. Crawford, Estrogens in the treatment of prostate cancer. J Urol, 1995. 154 (6): p. 1991-8.
266. Mikkola, A., et al., Ten-year survival and cardiovascular mortality in patients with advanced prostate cancer primarily treated by intramuscular polyestradiol phosphate or orchiectomy. Prostate, 2007. 67 (4): p. 447-55.
267. Hedlund, P.O., et al., Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer: part 2. Final evaluation of the Scandinavian Prostatic Cancer Group (SPCG) Study No. 5. Scand J Urol Nephrol, 2008. 42 (3): p. 220-9.
268. The Coronary Drug Project. Initial findings leading to modifications of its research protocol. JAMA, 1970. 214 (7): p. 1303-13.
269. Hulley, S., et al., Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA, 1998. 280 (7): p. 605-13.
270. Rossouw, J.E., et al., Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA, 2002. 288 (3): p. 321-33.
271. Santen, R.J., et al., Postmenopausal hormone therapy: an Endocrine Society scientific statement. J Clin Endocrinol Metab. 95 (7 Suppl 1): p. s1-s66.